Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00934011|
Recruitment Status : Completed
First Posted : July 8, 2009
Last Update Posted : February 3, 2016
|Condition or disease||Intervention/treatment||Phase|
|Severe Sepsis Septic Shock||Other: C-reactive protein guided antibiotic therapy Other: Procalcitonin guided antibiotic therapy||Not Applicable|
- Patients and settings: Prospective controlled randomized open interventional study of antibiotic therapy in adult with severe sepsis or septic shock, admitted to the intensive care unit.
The study will be conducted in the intensive care unit (ICU) of the University Hospital Risoleta Tolentino Neves of the Federal University of Minas Gerais, Brazil. This is a 30-bed ICU with medical and surgical patients. All patients with suspected severe sepsis or septic shock admitted to the ICU will be assessed for eligibility. Patients developing severe sepsis or septic shock during their ICU stay will be also considered for enrollment.
Cultures of urine, blood, bronchoalveolar lavage ﬂuid, and tracheal aspirates will be performed on admission and during ICU stay as clinically indicated. Blood gases and imaging exams will also be performed as clinically indicated, similarly in both groups.
All adult (> 17 years old) patients with diagnosis of severe sepsis or septic shock will receive initial antibiotic therapy based on local guidelines and susceptibility patterns, according to the decision of the treating physician. They will have circulating PCT and CRP levels measured at baseline and daily until day 4 in both groups.
Eligible patients will be reassessed on day 4 and randomized at 1:1 basis to one of the two groups since any exclusion criteria (see below) is present at that time:
Group 1 - CRP group: the duration of antibiotic therapy will be based on circulating CRP levels.
Group 2 - PCT group: the duration of antibiotic therapy will be based on circulating PCT levels.
Patients enrolled in the study will undergo daily measurements of plasma CRP (Dry Chemistry - Johnsons & Johnsons) and PCT (BRAHMS PCT VIDAS) levels up to stopping antibiotic therapy, every 48hr for two measurements in patients remaining in the ICU, and then, every 5 days.Patients will be followed up 28 days, or until death or hospital transference, which comes first. PCT and CRP results will be released in sealed envelopes. During the study period, only the results corresponding to the patient randomization group will be open; i.e., CRP for CRP group patients and PCT for PCT group patients.
- Criteria for antibiotic interruption:
The investigators will propose the interruption of antibiotics if:
- The patients is clinically stable, without signs of active infection
- CRP group: a relative reduction of 50% in baseline CRP levels, or a value lower than 25mg/dl is reached.
- PCT group: a relative reduction of 90% in baseline PCT levels, or if a absolute value lower than 0.1 ng/ml is reached.
The final decision regarding antibiotic therapy will be always let to the discretion of the treating physician.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||94 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Comparative Study of C-reactive Protein vs. Procalcitonin to Guide Antibiotic Therapy in Patients With Severe Sepsis and Septic Shock Admitted to the Intensive Care Unit.|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
Experimental: Group 1 - C-reactive protein (CRP) guided ab therapy
Intervention on antibiotic therapy will be based on circulating CRP levels
Other: C-reactive protein guided antibiotic therapy
plasma CRP measurement to guide the duration of antibiotic therapy
Active Comparator: Group 2 - procalcitonin (PCT) guided ab therapy
Intervention on antibiotic therapy will be based on circulating PCT levels
Other: Procalcitonin guided antibiotic therapy
plasma PCT measurement to guide the duration of antibiotic therapy
- Duration of antibiotic therapy for the first episode of infection [ Time Frame: 28 days ]
- Total antibiotic exposure days per 1,000 days [ Time Frame: 28 days ]
- Days alive without antibiotics [ Time Frame: 28 days ]
- All cause 28-day mortality [ Time Frame: 28 days ]
- clinical cure rate [ Time Frame: 28 days ]
- Infection relapse (diagnosed less than 48h after antibiotic discontinuation) [ Time Frame: 48 hours ]
- Length of ICU stay [ Time Frame: Whole hospitalization ]
- Nosocomial infection rate [ Time Frame: 28 days ]
- In-hospital mortality [ Time Frame: 28 days ]
- sepsis-associated death [ Time Frame: 28 days ]
- Nosocomial superinfection (diagnosed more than 48hous after discontinuation of the antibiotic therapy given to the first episode of infection) [ Time Frame: 28 days ]
- Isolation of resistant bacteria [ Time Frame: 28 days ]
- Length of hospital stay [ Time Frame: The whole hospitalization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00934011
|Hospital das Clínicas - Universidade Federal de Minas Gerais|
|Belo Horizonte, Minas Gerais, Brazil|
|Principal Investigator:||Vandack A Nobre, PhD||Medical School of the Federal University of Minas Gerais|
|Study Chair:||Carolina F Oliveira, MD||Idem|
|Study Chair:||Fernando A Botoni, PhD||Idem|